Pleural fluid cytology is already used in the diagnosis of cancer, especially metastatic disease, but its sensitivity may be limited. Tumor cells are easily obscured by the overwhelming number of background blood cells, and the cluster structure may be disrupted during processing. Although immunoaffinity approaches can detect malignant tumor cells (MTCCs), they may damage cells, dissociate malignant tumor cell clusters (MTCCs), or mask surface biomarkers with bound antibodies. Existing label-free microfluidic systems also face persistent trade-offs between throughput, purity, gentle handling, and the ability to separate single cells from clusters within the same platform. Based on these challenges, detailed studies on label-free, high-throughput, multiscale enrichment of both single tumor cells and intact clusters from clinical effusions need to be performed.
Researchers from Southeast University, Wuxi University of Science and Technology, and Southeast University Zhongda Hospital reported in 2026 (DOI: 10.1038/s41378-026-01235-y): Microsystems and nanoengineering They said they developed a cascade inertial microfluidic device to concentrate single and intact MTCCs from pleural effusions of lung cancer patients. The system uses parallel serpentine channels for first-stage background blood cell removal and inclined helical channels for second-stage size-based sorting. This study focused on clinical pleural fluid samples and sought a faster and less disruptive method to enrich tumor cells to enhance malignancy diagnosis and metastatic profiling.
This device operates on two linked classification steps. In the first stage, small blood cells are driven toward the sidewall and removed through the waste outlet, while larger target cells remain near the core stream for collection. In the second stage, a balance of inertial lift, Dean drag, and local vortex-induced forces separates single tumor cells from larger clusters depending on size. Using model particles, the system recovered 91.8% ± 6.6% of 25 μm particles representing clusters and 87.4% ± 7.4% of 15 μm particles representing single tumor cells. In a simulated cell test using A549 lung cancer cells and white blood cells (WBC), the total recovery rate of A549 reached 81.7% ± 1.2%, and the overall purity was 76.1% ± 1.3%. Single cells collected at exit 3 showed a recovery of 75.9% ± 1.3% and purity of 75.8% ± 1.6%, whereas the cluster-enriched fraction at exit 4 reached a purity of 79.4% ± 3.4%. For pleural fluid samples from three patients, the chip processed 50 mL in 6.5 minutes at 8 mL/min, yielding 68% purity for a single MTC and 35% purity for an intact MTCC. Tumor cells were identified as DAPI+/Pan-CK+/CD45- by immunofluorescence.
“This study represents a more obvious form of liquid biopsy analysis,” the study suggests. “The key advance is not simply capturing more cancer cells, but recovering them in a manner that preserves their biological meaning.” By significantly reducing background blood cells while preserving intact clusters, this platform has the potential to give cytology a clearer picture of both tumor burden and metastatic behavior. This finding further indicates that side-by-side enrichment of single cells and clusters may provide clinicians with a more complete picture of malignancy than traditional detection strategies that focus primarily on isolated cells.
The implications of this study are not only diagnostic but also practical. The chip is label-free, requires no external fields or complex equipment, and is compatible with standard downstream staining and microscopic analysis. Its multilayer polymer structure is also described as being suitable for scalable and relatively low-cost manufacturing. At the same time, the authors note that clinical validation is still preliminary and included only three patient samples, so larger cohorts are needed to establish diagnostic sensitivity and prognostic value. Nevertheless, this platform offers a promising path towards faster cytology support, better recovery of vulnerable tumor clusters, and more practical assessment of the malignancy of pleural effusions.
sauce:
Chinese Academy of Sciences
Reference magazines:
Zhu, Z. Others. (2026). Cascade inertial microfluidics for high-throughput and multiscale enrichment of tumor cells and intact clusters for enhanced malignancy diagnosis. Microsystems and nanoengineering. DOI: 10.1038/s41378-026-01235-y. https://www.nature.com/articles/s41378-026-01235-y
